Racial response to angiotensin-converting enzyme therapy in systolic heart failure.

Daniel J. Dries, Clyde W. Yancy, Mark A. Strong, Mark H. Drazner

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The treatment of heart failure with angiotensin-converting enzyme inhibitors has resulted in substantial improvements in morbidity and mortality due to heart failure. Varying reports in the literature have suggested that African Americans respond less well to angiotensin-converting enzyme inhibitors, but careful reanalysis of major clinical trials in heart failure, especially the Studies of Left Ventricular Dysfunction (SOLVD), demonstrates a similar mortality benefit for African Americans as for whites. Morbidity, measured as hospitalizations, may not be as favorably impacted. African Americans do respond to angiotensin-converting enzyme inhibitors as a preemptive strategy to prevent heart failure, but the incidence of heart failure is still higher in this population. Mechanisms for these potential nuances in the response to angiotensin-converting enzyme inhibitors are not yet clear. The exaggerated benefit of nitrates and hydralazine implicates alterations in nitric oxide homeostasis. Race is an inadequate model to explain the observed differences. Careful translational research focusing on genetic patterns of disease may help resolve these outstanding questions.

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalCongestive heart failure (Greenwich, Conn.)
Issue number1
StatePublished - 2004

ASJC Scopus subject areas

  • Emergency Medicine
  • Emergency
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Racial response to angiotensin-converting enzyme therapy in systolic heart failure.'. Together they form a unique fingerprint.

Cite this